Innovative filtration technologies to shoulder responsibility for pharmaceuticals
Akshita Pacholi outlines why the filtration market is so important to the pharmaceutical industry and discusses its predicted growth in the near future.
List view / Grid view
Akshita Pacholi outlines why the filtration market is so important to the pharmaceutical industry and discusses its predicted growth in the near future.
Upholding biosafety standards in coronavirus vaccine development and manufacturing despite the acute worldwide need.
Validation of syringe filters for QC testing: The parameters that influence analyte binding to filters.
Pfizer spokesperson reveals supply chain challenges and late clinical trial results contributed to its COVID-19 vaccine production target for 2020 being halved.
An independent review has outlined the achievements of the UK's Vaccine Taskforce, finding it worked "at great pace" to bring a COVID-19 vaccine to patients.
In this article, Dr Jaime Shamonki, Generate Life Science’s CMO, discusses how newborn stem cells derived from umbilical cord tissue could make mesenchymal stem cells less expensive and variable to produce.
A group of hackers has sent phishing emails to various people involved in COVID-19 vaccine cold chain distribution to gain insight, IBM has revealed.
Practical Tips for Monomer/Aggregate and Fragment Content Monitoring of monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs).
Single-use systems come with their own extractables and leachables challenges. Although there are no formal guidelines yet, safety must be assessed.
Secure your Pharma analysis & QC - Take your journey through our small molecules and biologics analysis & QC regulatory compliant portfolio.
The UK's MHRA has given temporary emergency authorisation to Pfizer and BioNTech's COVID-19 vaccine, making it the first in the world to receive approval.
The pharmaceutical cold chain includes numerous participants – David Lewandowski discusses why this must be scalable to ensure efficient delivery of a COVID-19 vaccine.
UK Prime Minister Boris Johnson has announced a £20 million investment fund for medicine manufacturing and supply chains in the UK.
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.